Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01188499 · ClinicalTrials.gov registry record · Phase 1
Dose Escalation, Combination Chemotherapy Safety Study of Birinapant (TL32711), in Subjects With Advanced or Metastatic Solid Tumors
A Phase 1 study of Cancer, sponsored by TetraLogic Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 176
- Enrollment target
- 7
- Study locations
NCT01188499: Completed Phase 1 study of Cancer, sponsored by TetraLogic Pharmaceuticals.
NCT01188499 is a Phase 1 study of Cancer that has completed, run by TetraLogic Pharmaceuticals. The registered enrollment target is 176 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (95% lower). The trial reports 7 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01188499, a Phase 1 study of Cancer, has completed, sponsored by TetraLogic Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 176 participants
- Enrollment target
- 7
- Study locations
Study Summary
This is a dose escalation safety study of birinapant (TL32711) in combination with chemotherapy in subjects with advanced or metastatic solid tumors.
Conditions Studied
Interventions
- DRUG Birinapant
Study Locations (7)
Pennsylvania
- University of Pennsylvania Abramson Cancer Center - Philadelphia
- Fox Chase Cancer Center - Philadelphia
Texas
- Mary Crowley Cancer Research Center - Dallas
- South Texas Accelerated Research Therapeutics (START) - San Antonio
Florida
- Holy Cross Hospital - Fort Lauderdale
Michigan
- Barbara Ann Karmanos Cancer Center - Detroit
New York
- Roswell Park Cancer Institute - Buffalo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 176 participants |
| Start Date | 2010-10 |
| Est. Completion | 2014-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01188499
The ClinicalTrials.gov registry entry for NCT01188499 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 176 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (95% lower). The listed sponsor is TetraLogic Pharmaceuticals, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which Birinapant is the first listed.
NCT01188499 reports 7 study locations spanning 5 distinct geographic areas - top geographies include Pennsylvania, Texas, Florida.
Frequently Asked Questions
What is clinical trial NCT01188499 about?
NCT01188499 is a clinical study titled "Dose Escalation, Combination Chemotherapy Safety Study of Birinapant (TL32711), in Subjects With Advanced or Metastatic Solid Tumors". This is a dose escalation safety study of birinapant (TL32711) in combination with chemotherapy in subjects with advanced or metastatic solid tumors.
What is the current status of trial NCT01188499?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 176 participants. The study started on 2010-10. Estimated completion is 2014-03.
What conditions does trial NCT01188499 study?
This clinical trial studies the following conditions: Cancer.
What interventions are being tested in trial NCT01188499?
The interventions under investigation include: Birinapant (DRUG).
Who is sponsoring clinical trial NCT01188499?
This trial is sponsored by TetraLogic Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01188499 being conducted?
This trial has 7 study locations across Florida, Michigan, New York, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Impact of Daily Oral Cannabis Doses in Patients With Cancer
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.